TMPRSS2 and COVID-19: Otamixaban was shown to be safe but lack efficacy relative to the control arm.35 Otamixaban was first identified as a drug repurposing candidate as an inhibitor of TMPRSS2 within a virtual screen.36 Corroborating data came from the Noe lab and our group that included computational, biochemical and cellular data to demonstrate its inhibition of TMPRSS2.12, 13 It has yet to enter clinical trials as an antiviral treatment for COVID-19.